Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 2/20 | 0.41 |
| ▸ | VNN1 | O95497 | 10/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20619561 | 0.90 | VNN1 (0.39) | VNN1ALDH1A1MAPK1CYP2C19LRRK2 | |
| SCHEMBL19699773 | 0.86 | RBP4 (0.42) | RBP4PKM | |
| SCHEMBL18395148 | 0.82 | PKM (0.47) | RBP4ALDH1A1PKM | |
| SCHEMBL20618190 | 0.81 | ABCC1 (0.37) | VNN1ALDH1A1SMN1; SMN2PKMLRRK2 | |
| SCHEMBL20619918 | 0.78 | SCN10A (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL25389483 | 0.78 | RBP4 (0.44) | RBP4 | |
| SCHEMBL20598365 | 0.77 | KMT2A (0.51) | RBP4VNN1ALDH1A1CYP2C19SMN1; SMN2 | |
| SCHEMBL20618429 | 0.76 | LRRK2 (0.36) | VNN1LRRK2 | |
| SCHEMBL17674350 | 0.75 | OGA (0.38) | VNN1 | |
| SCHEMBL20622176 | 0.75 | KIF18A (0.32) | ALDH1A1MAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11534439-B2 | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220016112-A1 | DIHYDROQUINOXALINE AND DIHYDROPYRIDOPYRAZINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2022-01-20 | — | — | US | disclosed |
| WO-2022010882-A1 | DIHYDROQUINOXALINE AND DIHYDROPYRIDOPYRAZINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC, (US) | 2022-01-13 | — | — | WO | disclosed |
| US-11179400-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200323872-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2020-10-15 | — | — | US | disclosed |
| WO-2020210246-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC, (US) | 2020-10-15 | — | — | WO | disclosed |
| US-20190002479-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11534439-B2 | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors | SIRT5, QDPR, NOX5 | RBP4 1846/4885VNN1 1334/4885ALDH1A1 668/4885 |
| US-20200323872-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | RBP4 2685/4885VNN1 755/4885ALDH1A1 721/4885 |
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | RBP4 2685/4885VNN1 755/4885ALDH1A1 721/4885 |
| US-20190002479-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | RBP4 2685/4885VNN1 755/4885ALDH1A1 721/4885 |
| US-11179400-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | RBP4 2685/4885VNN1 755/4885ALDH1A1 721/4885 |
| US-20220016112-A1 | DIHYDROQUINOXALINE AND DIHYDROPYRIDOPYRAZINE DERIVATIVES AS RSV INHIBITORS | SIRT5, QDPR, NOX5 | RBP4 1846/4885VNN1 1334/4885ALDH1A1 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.